## Case report

# Microscopic polyangiitis associated with subarachnoid hemorrhage

Katsuhito Ihara<sup>1</sup>, Makiko Kimura<sup>1</sup>, Megumi Yamamuro<sup>1</sup>, and Seiji Inoshita<sup>1</sup>

<sup>1</sup> Department of Internal Medicine, Tokyo Metropolitan Bokutoh Hospital, Japan

### Abstract

Microscopic polyangiitis (MPA), an anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, is a systemic disease that damages all organs through predominantly affecting small vessels. However, few cases of MPA are related to aneurysms on medium-sized muscular vessels, and whether subarachnoid hemorrhage (SAH) is associated with MPA is still unclear. An 85-yearold woman with rapid progressive glomerular nephritis caused by MPA complained of sudden severe headache due to SAH 2 days after admission and subsequently underwent surgery. Cerebrovascular disease occurring simultaneously with MPA might result in poor prognosis, and the complications exacerbate the condition and lead to high mortality; thus, physicians should pay more attention to cerebral aneurysms concurrent with MPA. Among patients with MPA, it is important to identify priority cases and investigate the intracranial vessel environment. To the best of our knowledge, this is a rare report about SAH associated with MPA. We recommend that the presence of cerebrovascular disease should be considered in patients with MPA to improve their prognosis.

Key words: ANCA-associated vasculitis, microscopic polyangiitis, subarachnoid hemorrhage, cerebral aneurysm, prognosis

(J Rural Med 2019; 14(1): 125–131)

# Introduction

The Chapel Hill Consensus Conference (CHCC) has played an important role in classifying primary vasculitis based on the size of the affected vessels<sup>1</sup>). Under this classification, anti-neutrophil cytoplasmic antibody (ANCA) is a common pathologic factor in vasculitis of small vessels, called ANCA-associated vasculitis (AAV). While granulomatosis with polyangiitis (GPA) is more common in the United States and Europe, microscopic polyangiitis (MPA) is the major AAV in Japan, and it mainly affects the kidneys and lungs<sup>2, 3</sup>). MPA is defined as pauci-immune necrotizing vasculitis predominantly affecting small vessels. Hence, MPA is known to be a systemic disease that damages every organ involved with small vessels, namely the lungs, kidneys, skin, and peripheral nervous system.

In general, few cases of MPA are related to aneurysm formation on medium-sized muscular vessels, although CHCC classification describes the possibility of necrotizing arteritis involving small and medium arteries in MPA<sup>1</sup>. As a result, cerebral aneurysms are rarely encountered among patients with MPA. Therefore, whether subarachnoid hemorrhage (SAH) is associated with MPA is unclear.

However, we encountered an 85-year-old woman who had SAH concurrent with MPA, and hypothesized that the SAH might be associated with MPA. Thus, this is a rare report about SAH associated with MPA.

## **Case Report**

An 85-year-old woman complained of anorexia for 1 month prior to admission. She also experienced abdominal pain, leading to lower intake of food and water. She showed extreme dehydration and loss of body weight. Eventually, she was admitted to our hospital for anorexia, abdominal pain, and fatigue, which had resulted in renal dysfunction and hyperkalemia. Her medical history included postoperative uterine myoma, pancreatic neuroendocrine tumor with conservation strategy, grade C–D reflux esophagitis according to the Los Angeles classification 21 months before admission, and right renal cell carcinoma completely excluded

Received: April 18, 2018

Accepted: October 9, 2018

Correspondence: Katsuhito Ihara, Department of Internal Medicine, Tokyo Metropolitan Bokutoh Hospital, 4-23-15 Kotobashi, Sumida-ku, Tokyo 130-8575, Japan

E-mail: ctngt512@yahoo.co.jp

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <a href="http://creativecommons.org/licenses/by-nc-nd/4.0/>">http://creativecommons.org/licenses/by-nc-nd/4.0</a>.

by operation 13 months prior to the present admission. Her younger brother had died of cholangiocarcinoma, and her mother had leukemia. The patient denied alcohol use, smoking, and any allergies. She was administered esomeprazole and magnesium hydroxide. On admission, her consciousness was lucid; she had a height of 143.3 cm, body weight of 57.5 kg, body mass index of 28.0 kg/m<sup>2</sup>, body temperature of 36.7°C, blood pressure of 158/67 mmHg, pulse of 65 beats per minute, and oxygen saturation of 97% in room air. Physical examination revealed anemia on palpebral conjunctiva, severely dry tongue, and edema of the extremities. The neck, heart, lung, and abdomen revealed no abnormalities. The results of the laboratory tests demonstrated urinary abnormalities, anemia, hypoalbuminemia, renal dysfunction, electrolyte abnormalities, metabolic acidosis, and elevation of C-reactive protein level (Table 1). In comparison to her past renal function with an estimated glomerular filtration rate of 50-59 mL/min/1.73 m<sup>2</sup> and a normal urinary status 1 month prior to the present admission, the exacerbation of her renal function indicated rapid progressive glomerulonephritis (RPGN). A few days after submission of the laboratory tests, the results revealed that the serum titer of MPO-ANCA was 444.0 IU/mL using the Fluorescence Enzyme Immunoassay (normal < 5.0 IU/mL). Chest radiograph and computed tomography (CT) examinations showed no abnormalities in the lung field (Figure 1a, b). The left kidney was swollen (101  $\times$  59 mm) but revealed no hydronephrosis (Fig. 1c). Transthoracic echocardiography showed no vegetation on the cardiac valves, and both sets of blood cultures showed negative results. Renal biopsy was not performed, as the patient had only the left kidney. Based on the CHCC classification<sup>1)</sup> and clinical practice guideline for ANCA-associated vasculitis<sup>4</sup>, vasculitides induced by malignancy condition, systemic disease (e.g., rheumatoid arthritis, systemic lupus erythematosus), infections (e.g., infective endocarditis, hepatitis C, and tuberculosis), and drugs (e.g., propylthiouracil, hydralazine, minocycline)<sup>5)</sup> was excluded. Since MPO-ANCA was positive (Table 1) and as "findings of a positive ANCA should suggest the diagnosis of small vessel vasculitis such as MPA, GPA, or eosinophilic granulomatosis with polyangiitis (EGPA)"5), the patient was diagnosed with AAV rather than immune complex small vessel vasculitis. After excluding EGPA and GPA, and confirming the RPGN with urinary exacerbation, she was eventually diagnosed with MPA. The severity of her vasculitis was equivalent to 14 points in the Birmingham Vasculitis Activity Score<sup>6)</sup> and 7 points in the Renal Severity Classification, which is equal to grade III according to the clinical guideline for RPGN<sup>7</sup>).

Subsequently, a therapeutic strategy against MPA was planned. However, the patient suddenly complained of severe headache and nausea on the third day of hospitalization. Her blood pressure was 180/110 mmHg, and she vomited several times. Cranial CT indicated a high-density area in the basal cistern corresponding to SAH and mild hydrocephalus (Figure 2a). Moreover, digital subtraction angiography revealed a fusiform and a saccular-like aneurysm sharing their neck, arising from the right middle cerebral artery (Figure 2b, c). Based on the location of the subarachnoid hematoma, it was concluded that the SAH was attributed to the rupture of the right middle cerebral artery aneurysm, and emergent neck clipping was performed. Although a premature rupture occurred upon the dissection of the neck of the aneurysm, bleeding was well controlled through application of a temporary clip. The neck clipping was accomplished in the usual manner followed by ventricular drainage owing to the tight posterior fossa. The SAH of the patient was classified as grade II, I, and 3 according to the World Federation of Neurosurgical Societies, Hunt & Kosnik, and Fischer classifications, respectively. Despite the successful operation, her postoperative consciousness was poor, which scored 9 points (E3V1M5) on the Glasgow Coma Scale; unfortunately, we never communicated with her after the event. To introduce remission and avoid further occurrence of any complications from MPA, she was administered intravenous methylprednisolone (0.5 g/day for three doses) followed by oral prednisolone at 30 mg/ day (0.5 mg/kg/day). Considering the deterioration of her renal function owing to RPGN, the patient was started on renal replacement therapy (RRT) via a catheter until her renal function recovered. Intermittent hemodialysis was performed owing to her stable hemodynamic condition. After the initiation of steroid therapy and RRT, her renal function gradually recovered, and we were able to withdraw RRT as the titer value of MPO-ANCA became negative (Figure 3). The patient never experienced SAH, or cardiovascular or cerebrovascular events. Prophylaxis against infection was started soon after the immunosuppressive therapy; however, repeated instances of infectious diseases including pneumonia, urinary tract, and catheter-related blood stream infections were observed. Unfortunately, the patient died of infection on Day 135 of hospitalization.

## Discussion

From the findings of this study, we confirmed two important clinical issues: 1) cerebrovascular disease concurrent with MPA leads to poor prognosis, and 2) more attention should be paid to cerebral aneurysms complicated with MPA.

First, patients with cerebrovascular disease simultaneous with MPA tend to have poor prognosis. Table 2 demonstrates the poor prognoses in patients with MPA once

| blood tests | values                     | (continues)         |                | urinalysis                    | values       |
|-------------|----------------------------|---------------------|----------------|-------------------------------|--------------|
| WBC         | 10400 /µL                  | T-Bil               | 0.4 mg/dL      | protein                       | 2+           |
| neutrophils | 90.1%                      | CK                  | 11 U/L         | glucose                       | _            |
| lymphocyte  | 5.4%                       | BS                  | 100 mg/dL      | gravity                       | 1.012        |
| monocyte    | 3.1%                       | HbA1 <sub>c</sub>   | 5.9 %(NGSP)    | pН                            | 5.5          |
| eosiophils  | 1.2%                       | AMY                 | 41 U/L         | urobilinogen                  | ±            |
| basophils   | 0.2%                       | TG                  | 112 mg/dL      | bilirubin                     | _            |
| RBC         | $283 \times 10^4 / \mu L$  | LDL-C               | 72 mg/dL       | ket                           | _            |
| Hb          | 8.6 g/dL                   | Fe                  | 21 µg/dL       | WBC                           | 2+           |
| Ht          | 25.50%                     | TIBC                | 158 μg/dL      | nitrate                       | _            |
| MCV         | 90 fL                      | ferrtin             | 232.7 ng/dL    | occult blood                  | 3+           |
| MCH         | 30.3 pg                    | CRP                 | 11.1 mg/dL     | bacteria                      | 3+           |
| MCHC        | 33.70%                     | KL-6                | 165 U/mL       | RBC                           | 10–19 /hpf   |
| Plt         | $39.6 \times 10^4 / \mu L$ | SP-D                | 29.7 ng/mL     | WBC                           | 1–4 /hpf     |
| PT          | 55.90%                     | (1-3) β-D Glucan    | < 6.0 pg/mL    | epitherial cells              | 1-4 /hpf     |
| PT-INR      | 1.23                       | free T <sub>3</sub> | 1.43 pg/mL     | granular cast                 | 1-4 /WF      |
| aPTT        | > 130.0 sec                | free T <sub>4</sub> | 1.06 ng/dL     | TP                            | 149 mg/dL    |
| fibrinogen  | 501 mg/dL                  | TSH                 | 1.96 µU/mL     | Cr                            | 59.9 mg/dL   |
| D-dimer     | 10 μg/mL                   | BNP                 | 619.5 pg/mL    | Na                            | 54 mEq/L     |
| FDP         | 24 μg/mL                   | HBs Antigen         | _              | Cl                            | 54 mEq/L     |
| AT-III      | 67.40%                     | HBs Antibody        | 85.7 mIU/mL    | K                             | 34 mEq/L     |
| ТР          | 6.3 g/dL                   | HBc Antibody        | 1.16 INH%      | urinary collection            | value        |
| Alb         | 2.2 g/dL                   | HCV Antibody        | _              | ТР                            | 0.515 g/day  |
| BUN         | 75 mg/dL                   | RPR                 | _              | UN                            | 1.698 g/day  |
| Cr          | 6 mg/dL                    | TPLA                | _              | Cr                            | 0.256 g/day  |
| UA          | 9.5 mg/dL                  | IgG                 | 1664 mg/dL     | Na                            | 43.2 mEq/day |
| Na          | 124 mEq/L                  | IgM                 | 106 mg/dL      | Cl                            | 48.6 mEq/day |
| Κ           | 7.4 mEq/L                  | IgA                 | 339 mg/dL      | K                             | 15 mEq/day   |
| Cl          | 98 mEq/L                   | C <sub>3</sub>      | 76 mg/dL       | unine volume                  | 600 mL/day   |
| Ca          | 8 mg/dL                    | C <sub>4</sub>      | 14 mg/dL       | arterial blood gas            | values       |
| iP          | 5.5 mg/dL                  | CH <sub>50</sub>    | 52 U/mL        | рН                            | 7.367        |
| LDH         | 252 U/L                    | cryoglobulin        | _              | PCO <sub>2</sub>              | 28.6 mmHg    |
| AST         | 10 U/L                     | ANA (homogenous)    | 20 times       | PO2                           | 102 mmHg     |
| ALT         | 7 U/L                      | Anti GBM Antibody   | 2.3 U/mL FEIA  | HCO <sub>3</sub> <sup>-</sup> | 16 mmol/L    |
| γGTP        | 13 U/L                     | MPO-ANCA            | 444 IU/mL FEIA | Na <sup>+</sup>               | 128 mmol/L   |
| ALP         | 208 U/L                    | PR3-ANCA            | 1 IU/mL FEIA   | Cl                            | 102 mmol/L   |

 Table 1
 Laboratory tests upon admission

Hb: hemoglobin, Ht: hematocrit, Plt: platelet, PT: prothrombin time, PT-INR: prothrombin time-international normalized ratio, aPTT: activated partial thromboplastin time, FDP: fibrin degradation product, AT-III: antithrombin III, TP: total protein, Alb: albumin, BUN: blood urea nitrogen, Cr: serum creatinine, UA: uric acid, LDH: lactic acid dehydrogenase, AST: aspartate aminotransferase, ALT: alanine aminotransferase, γGTP: γ-glutamyltranspeptidase, ALP: alkaline phosphatase, T-Bil: total bilirubin, CK: creatine kinase, BS: blood sugar, AMY: amylase, TG: triglyceride, LDL-C: low-density lipoprotein cholesterol, TIBC: total iron-binding capacity, CRP: C-reactive protein, SP: surfactant protein, TSH: thyroid-stimulating hormone, BNP: brain natriuretic peptide, ANA: antinuclear antibody, GBM: glomerular basement membrane, MPO-ANCA: myeloperoxidase antineutrophil cytoplasmic antibody. The extension time of aPTT was due to the disoperation of sample distribution.

cerebrovascular accidents occur<sup>8–16)</sup>. In addition, when considering the time to event after admission, we noticed that these events strike during active phases of the vasculitides. Despite successful operations in patients with SAH after the rupture of cerebral aneurysms, patients with MPA tend to experience various complications, as observed in our case, because most of them tend to undergo immunosuppressive therapy. Under these circumstances, not only SAH but also the complications from immunosuppression (e.g., infectious diseases) would exacerbate the condition and lead to high mortality. Although there is no report about the prognosis of the association between SAH and immunocompromised



Figure 1 (a) (b) Lung field showed no abnormalities on chest radiography or computed tomography (CT). (c) Left kidney was swollen on abdominal CT.



Figure 2 (a) Computed tomography of the head showed subarachnoid hemorrhage, mainly located in the cisterna magna and mild hydrocephalus. (b) (c) Digital subtraction angiography revealed a fusiform and a saccular-like aneurysm sharing their neck, arising from the right middle cerebral artery (arrows).



Figure 3 Clinical course after admission to hospital.

SAH: subarachnoid hemorrhage; RRT: renal replacement therapy; m-PSL: methylprednisolone; PSL: prednisolone; ABx: antibiotics; CRBSI: catheter-related blood stream infection; CRP: C-reactive protein; Cr: serum creatinine; MPO-ANCA: myeloperoxidase antineutrophil cytoplasmic antibody.

state, we could recognize the poorer prognosis of SAH concurrent with MPA based on our experience. Hence, we recommend that the presence of cerebrovascular disease should be anticipated in patients who show positive results for MPO-ANCA, in order to improve the prognoses of these patients.

Second, more attention has to be paid to cerebral aneurysms associated with MPA. Although aneurysms of medium-sized vessels are rarely reported in MPA<sup>17)</sup> and little is known about their accurate pathogenesis and mechanisms in aneurysm formation, MPA could be related to arteritis of both small- and medium-sized vessels and aneurysm formation. Firstly, approximately 23% of MPA cases were reported to be involved with the medium-sized renal artery<sup>18)</sup>. Secondly, one report hypothesized that debilitating vessel walls and aneurysm formation result from necrotizing changes<sup>19)</sup>. For instance, Kimura *et al.* reported a case of SAH derived from pseudoaneurysm on the posterior inferior cerebellar artery, which was histologically consistent with MPA9 (Table 2). Two cases of MPA reported both necrotizing changes and intrarenal aneurysms<sup>20, 21)</sup>, and an autopsy case of a 74-year-old man with MPA leading to intraabdominal hemorrhage revealed medium-sized arteritis and rupture of a pseudoaneurysm on a branch of the left gastric artery<sup>22)</sup>. Lastly, CHCC classification specifies that "ANCAs are not associated with polyarteritis nodosa (PAN)" for discriminating from AAV because "PAN and AAV can exhibit clinically and pathologically indistinguishable necrotizing arteritis of medium and small ateries"1). Therefore, we could consider that the medium-sized vasculitides are derived from MPA when patients show positive results for ANCAs. Despite the low prevalence of cerebral aneurysm formation complicated with MPA, our case indicates an association between SAH and MPA. This will enable the provision of interventions for cerebral aneurysms before they rupture.

In conclusion, cerebrovascular disease occurring simultaneously with MPA might result in poor prognosis; thus, physicians should pay more attention to cerebral aneurysms

| lable. | L Frevious report                      | s about ce  | rebrovascular disease i               | in patients with h                  | AFA                     |   |  |  |                       |          |
|--------|--|-------------|---------------------------------------|-------------------------------------|-------------------------|---|--|--|-----------------------|----------|
| Case   | Reference                              | Age/Sex     | Cerebrovascular<br>diseases           | Time to event<br>after admission    | Aneurysms               | Biopsy  | Responsible areas                        | Complications                                      | ANCA                  | Outcome  |
| -      | Isoda <i>et al.</i> <sup>10)</sup>     | 72/M        | cerebral infarction<br>and hemorrhage | 8 days                              | Yes<br>(renal artery)   | Not performed   | right thalamus                           | RPGN<br>polyneuropathy                             | MPO-ANCA<br>330 EU    | Survival |
| 2      | Kimura <i>et al.</i> <sup>11)</sup>    | 44/M        | subarachnoid<br>hemorrhage            | 2 days                              | Yes<br>(pseudoaneurysm) | fibrin layer<br>inflammatory cell<br>infiltration in aneurysm                                 | posterior inferior<br>cerebellar artery  | RPGN   | MPO-ANCA<br>312 EU    | Survival |
| ŝ      | Yamashiro <i>et al.</i> <sup>12)</sup> | 67/F        | cerebral infarction                   | N/A                                 | No                      | Not performed   | left thalamus                            | microscopic<br>hematuria<br>alveolar<br>hemorrhage | MPO-ANCA<br>51.2 U/ml | N/A      |
| 4      | Sasaki <i>et al.</i> <sup>13)</sup>    | 78/M        | cerebral hemorrhagic<br>infarction    | on admission                        | No                      | necrotizing angiitis<br>in cerebral vessels   | cerebral cortex                          | RPGN<br>alveolar<br>hemorrhage                     | N/A                   | Dead     |
| S      | Ito <i>et al.</i> <sup>14)</sup>       | 56/M        | cerebral hemorrhage<br>and infarction | 5 days                              | No                      | hypertrophic endothelial cells<br>perivascular inflammation<br>at perioheral nerve            | bilateral corona<br>radiata              | polyneuropathy                                     | MPO-ANCA<br>640 U     | Dead     |
| 9      | Han <i>et al.</i> <sup>15)</sup>       | 43/M        | cerebral hemorrhage                   | 9 days                              | No                      | leucocytoclasic vasculitis<br>in cerebral vessels   | N/A                                      | RPGN   | PR3-ANCA<br>40.0 U/ml | Dead     |
| Г      | Tang et al. <sup>16)</sup>             | 55/M        | cerebral infarction                   | on addmission                       | No                      | leukocytoclastic venulitis<br>in skin   | bilateral basal<br>ganglionic infarction | No   | MPO-ANCA<br>22 U/ml   | Survival |
| ∞      | Iyoda <i>et al.</i> <sup>17)</sup>     | 60/F        | cerebral hemorrhage                   | one day<br>between 2 and<br>26 days | N/A                     | necrotizing crescentic<br>glomerulonephritis<br>renal arteriolitis with<br>fibrinoid necrosis | cerebral cortex                          | RPGN<br>pulmonary<br>hemorrhage                    | MPO-ANCA<br>1,230 EU  | Dead     |
| 6      | Ku et al. <sup>18)</sup>               | 66/F        | multiple<br>cerebral infarctions      | 25 days                             | No                      | perivascular inflammation<br>with occlusion in<br>peripheral nerve                            | corona radiate<br>basal ganglia          | neuropathy   | MPO-ANCA<br>1,719 AAU | Survival |
| MPA: n | nicroscopic polyang                    | șiitis, ANC | A: anti-neutrophil cytop              | lasmic antibody, l                  | RPGN: rapid progres     | sive glomerulonephritis, MPO:   | myeloperoxidase, PR                      | 3: proteinase 3, N//                               | A: not applicable     |          |

vith MPA 4 ÷. ÷ ÷ ÷ ÷  $\mathbf{p}_{re}$ Tahle 7

130

concurrent with MPA. As improvement of the prognosis of patients with cerebral aneurysms is possible before the rupture of blood vessels, MPA cases should be carefully investigated to identify the cases that should be prioritized and to determine the environment of intracranial vessels in these cases.

**Conflict of Interest:** The authors declare that no conflict of interest exists.

### References

- Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of vasculitides. Arthritis Rheum 2013; 65: 1–11. [Medline] [CrossRef]
- Suzuki Y, Takeda Y, Sato D, *et al.* Clinicoepidemiological manifestations of RPGN and ANCA-associated vasculitides: an 11-year retrospective hospital-based study in Japan. Mod Rheumatol 2010; 20: 54–62. [Medline] [CrossRef]
- Ozaki S. Clinical trial for Japanese patients with myeloperoxidase anti-neutrophil cytoplasmic antibody-associated vasculitis: the JMAAV study. Clin Exp Nephrol 2013; 17: 700–704. [Medline] [CrossRef]
- Ozaki S, Makino H, Matsuo S., editors. Clinical practice guideline for ANCA-associated vasculitis, 2011. (in Japanese).
- Gerald B. Appel, Jai Radhakrishnan and Vivette D'Agati. Small vessel vasculitis. in: Brenner and Rector's The Kidney. 10th ed. Karl Skorecki, Glenn M. Chcrtow, Philip A. Marsden, et al, Eds. Elsevier, Philadelphia, 2016; 1109–1117.
- Luqmani RA, Bacon PA, Moots RJ, *et al.* Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994; 87: 671–678. [Medline]
- Arimura Y, Muso E, Fujimoto S, *et al*. Evidence-based clinical practice guidelines for rapidly progressive glomerulonephritis 2014. Clin Exp Nephrol 2016; 20: 322–341. [Medline] [CrossRef]
- Isoda K, Nuri K, Shoda T, *et al.* Microscopic polyangiitis complicated with cerebral infarction and hemorrhage: a case report and review of literature. Nihon Rinsho Meneki Gakkai Kaishi 2010; 33: 111–115 (in Japanese, Abstract in English). [Medline] [CrossRef]
- Kimura H, Akutsu N, Shiomi R, *et al.* Subarachnoid hemorrhage caused by ruptured intracranial fusiform aneurysm associated with microscopic polyangiitis. Neurol Med Chir (Tokyo) 2012; 52: 495–498. [Medline] [CrossRef]
- 10. Yamashiro K, Mori A, Shimada Y, et al. Gradient echo T2\*-

weighted magnetic resonance imaging revealing cerebral microbleeds in a patient with microscopic polyangiitis complicated by cerebrovascular disease. J Stroke Cerebrovasc Dis 2012; 21: 904.e7–904.e9. [Medline] [CrossRef]

- Sasaki A, Hirato J, Nakazato Y, *et al.* [An autopsy case of P-ANCA-positive microscopic polyangiitis with multiple cerebral hemorrhagic infarction]. No To Shinkei 1998; 50: 56–60 (in Japanese, Abstract in English). [Medline]
- Ito Y, Suzuki K, Yamazaki T, *et al.* ANCA-associated vasculitis (AAV) causing bilateral cerebral infarction and subsequent intracerebral hemorrhage without renal and respiratory dysfunction. J Neurol Sci 2006; 240: 99–101. [Medline] [Cross-Ref]
- Han S, Rehman HU, Jayaratne PS, *et al.* Microscopic polyangiitis complicated by cerebral haemorrhage. Rheumatol Int 2006; 26: 1057–1060. [Medline] [CrossRef]
- Tang CW, Wang PN, Lin KP, *et al.* Microscopic polyangiitis presenting with capsular warning syndrome and subsequent stroke. J Neurol Sci 2009; 277: 174–175. [Medline] [Cross-Ref]
- Iyoda M, Ito J, Nagai H, *et al.* Microscopic polyangiitis after silicone breast implantation. Clin Exp Nephrol 2005; 9: 252–254. [Medline] [CrossRef]
- Ku BD, Shin HY. Multiple bilateral non-hemorrhagic cerebral infarctions associated with microscopic polyangiitis. Clin Neurol Neurosurg 2009; 111: 904–906. [Medline] [CrossRef]
- Guillevin L, Durand-Gasselin B, Cevallos R, *et al.* Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999; 42: 421–430. [Medline] [CrossRef]
- Zhao MH, Sun QZ, Wang HY. Clinical and pathological characterization of patients with microscopic polyangiitis with medium artery involvement. Ren Fail 2003; 25: 989–995. [Medline] [CrossRef]
- Mavrogeni S, Manoussakis MN, Karagiorga TC, *et al.* Detection of coronary artery lesions and myocardial necrosis by magnetic resonance in systemic necrotizing vasculitides. Arthritis Rheum 2009; 61: 1121–1129. [Medline] [CrossRef]
- Inatsu A, Shimizu J, Ooshima S, *et al*. Antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis with intrarenal aneurysms and renal arteriovenous fistulaes. Intern Med 2002; 41: 853–858. [Medline] [CrossRef]
- 21. Tamei N, Sugiura H, Takei T, *et al.* Ruptured arterial aneurysm of the kidney in a patient with microscopic polyangiitis. Intern Med 2008; 47: 521–526. [Medline] [CrossRef]
- Ito Y, Tanaka A, Sugiura Y, *et al.* An autopsy case of intraabdominal hemorrhage in microscopic polyangiitis. Intern Med 2011; 50: 1501–1502. [Medline] [CrossRef]